Carlotta Welters

Carlotta Welters

Auto-generated profile, based on publicly available information

Carlotta Welters

Department of Hematology, Oncology, and Tumor Immunology, Charit e-Universit€ atsmedizin Berlin, Corporate Member of Freie Universit€ at Berlin and

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Blood
Verified
Journal Article
Closed access
PDF file
AHAmin Ben Hamza
Amin Ben Hamza
CWCarlotta Welters
Carlotta Welters
SSSerena Stadler
Serena Stadler
MBMonika Brüggemann
Monika Brüggemann
KDKerstin Dietze
Kerstin Dietze
LHLeo Hansmann
Leo Hansmann
Acquired aplastic anemia is a bone marrow failure syndrome characterized by hypocellular bone marrow and peripheral blood pancytopenia. Frequent clinical responses to calcineurin inhibition and antithymocyte globulin strongly suggest critical roles for hematopoietic stem/progenitor cell–reactive T-cell clones in disease pathophysiology; however, their exact contribution and antigen specificities remain unclear. We determined differentiation states and targets of dominant T-cell clones along with their potential to eliminate hematopoietic progenitor cells in the bone marrow of 15 patients with acquired aplastic anemia. Single-cell sequencing and immunophenotyping revealed oligoclonal expansion and effector differentiation of CD8+ T-cell compartments. We reexpressed 28 dominant T-cell receptors (TCRs) of 9 patients in reporter cell lines to determine reactivity with (1) in vitro–expanded CD34+ bone marrow, (2) CD34− bone marrow, or (3) peptide pools covering immunodominant epitopes of highly prevalent viruses. Besides 5 cytomegalovirus-reactive TCRs, we identified 3 TCRs that recognized antigen presented on hematopoietic progenitor cells. T cells transduced with these TCRs eliminated hematopoietic progenitor cells of the respective patients in vitro. One progenitor cell–reactive TCR (11A5) also recognized an epitope of the Epstein-Barr virus–derived latent membrane protein 1 (LMP1) presented on HLA-A∗02:01. We identified 2 LMP1-related mimotopes within the human proteome as activating targets of TCR 11A5, providing proof of concept that molecular mimicry of viral and self-epitopes can drive T cell–mediated elimination of hematopoietic progenitor cells in aplastic anemia.

19 September 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
CWCarlotta Welters
Carlotta Welters
MCMaría Fernanda Lammoglia Cobo
María Fernanda Lammoglia Cobo
CSChristian Alexander Stein
Christian Alexander Stein
MHMeng-Tung Hsu
Meng-Tung Hsu
AHAmin Ben Hamza
Amin Ben Hamza
LHLeo Hansmann
Leo Hansmann
Multiple myeloma is a hematologic malignancy of monoclonal plasma cells that accumulate in the bone marrow. Despite their clinical and pathophysiologic relevance, the roles of bone marrow–infiltrating T cells in treatment-naïve patients are incompletely understood. We investigated whether clonally expanded T cells (i) were detectable in multiple myeloma bone marrow, (ii) showed characteristic immune phenotypes, and (iii) whether dominant clones recognized antigens selectively presented on multiple myeloma cells. Single-cell index sorting and T-cell receptor (TCR) αβ sequencing of bone marrow T cells from 13 treatment-naïve patients showed dominant clonal expansion within CD8+ cytolytic effector compartments, and only a minority of expanded T-cell clones expressed the classic immune-checkpoint molecules PD-1, CTLA-4, or TIM-3. To identify their molecular targets, TCRs of 68 dominant bone marrow clones from five selected patients were reexpressed and incubated with multiple myeloma and non–multiple myeloma cells from corresponding patients. Only 1 of 68 TCRs recognized antigen presented on multiple myeloma cells. This TCR was HLA-C–restricted, self-peptide–specific and could be activated by multiple myeloma cells of multiple patients. The remaining dominant T-cell clones did not recognize multiple myeloma cells and were, in part, specific for antigens associated with chronic viral infections. In conclusion, we showed that dominant bone marrow T-cell clones in treatment-naïve patients rarely recognize antigens presented on multiple myeloma cells and exhibit low expression of classic immune-checkpoint molecules. Our data provide experimental context for experiences from clinical immune-checkpoint inhibition trials and will inform future T cell–dependent therapeutic strategies.

4 May 2022 in Cytotherapy
Verified
Journal Article
Open access
MCMaría Fernanda Lammoglia Cobo
María Fernanda Lammoglia Cobo
CWCarlotta Welters
Carlotta Welters
LRLeonie Rosenberger
Leonie Rosenberger
MLMatthias Leisegang
Matthias Leisegang
KDKerstin Dietze
Kerstin Dietze
LHLeo Hansmann
Leo Hansmann
Epstein-Barr virus (EBV) is associated with solid and hematopoietic malignancies. After allogeneic stem cell transplantation, EBV infection or reactivation represents a potentially life-threatening condition with no specific treatment available in clinical routine. In vitro expansion of naturally occurring EBV-specific T cells for adoptive transfer is time-consuming and influenced by the donor's T-cell receptor (TCR) repertoire and requires a specific memory compartment that is non-existent in seronegative individuals. The authors present highly efficient identification of EBV-specific TCRs that can be expressed on human T cells and recognize EBV-infected cells. Mononuclear cells from six stem cell grafts were expanded in vitro with three HLA-B*35:01- or four HLA-A*02:01-presented peptides derived from six EBV proteins expressed during latent and lytic infection. Epitope-specific T cells expanded on average 42-fold and were single-cell-sorted and TCRαβ-sequenced. To confirm specificity, 11 HLA-B*35:01- and six HLA-A*02:01-restricted dominant TCRs were expressed on reporter cell lines, and 16 of 17 TCRs recognized their presumed target peptides. To confirm recognition of virus-infected cells and assess their value for adoptive therapy, three selected HLA-B*35:01- and four HLA-A*02:01-restricted TCRs were expressed on human peripheral blood lymphocytes. All TCR-transduced cells recognized EBV-infected lymphoblastoid cell lines. The authors' approach provides sets of EBV epitope-specific TCRs in two different HLA contexts. Resulting cellular products do not require EBV-seropositive donors, can be adjusted to cell subsets of choice with exactly defined proportions of target-specific T cells, can be tracked in vivo and will help to overcome unmet clinical needs in the treatment and prophylaxis of EBV reactivation and associated malignancies.

7 January 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
SSSerena Stadler
Serena Stadler
RBRafael B. Blasco
Rafael B. Blasco
VSVijay Kumar Singh
Vijay Kumar Singh
CDChristine Damm-Welk
Christine Damm-Welk
ABAmin Ben-Hamza
Amin Ben-Hamza
WWWilhelm Woessmann
Wilhelm Woessmann
Anaplastic lymphoma kinase (ALK) fusion proteins resulting from chromosomal rearrangements are promising targets for cancer immunotherapy. Although ALK-specific CD8+ T cells and epitopes presented on MHC class I have been identified in patients with ALK-positive malignancies, little is known about ALK-specific CD4+ T cells. We screened peripheral blood of 10 patients with ALK-positive anaplastic large-cell lymphoma in remission and six healthy donors for CD4+ T-cell responses to the whole ALK fusion protein, nucleophosmin 1 (NPM1)::ALK. ALK-specific CD4+ T cells were detected in 15 individuals after stimulation with autologous dendritic cells pulsed with long-overlapping ALK peptide pools. CD4+ T-cell epitopes were predominantly located within three specific regions (p102-188, p257-356, and p593-680) in the ALK portion of the fusion protein. We detected CD4+ T cells in one patient that recognized the NPM1::ALK fusion neoepitope and identified a corresponding T-cell receptor (TCR) by TCRαβ single-cell sequencing. The NPM1::ALK fusion–specific TCR was HLA-DR13–restricted and conferred antigen specificity when expressed in a TCR− reporter cell line (58α−β−). Together, our data provide evidence of ALK-specific CD4+ T cells in human peripheral blood, describe target epitopes in patients, and support the consideration of CD4+ T cells in the development of ALK-specific immunotherapies.

19 March 2024 in European Journal of Immunology
Verified
Journal Article
Open access
MWMarthe‐Lina Welters
Marthe‐Lina Welters
SSSerena Stadler
Serena Stadler
VAVasiliki Anastasopoulou
Vasiliki Anastasopoulou
LBLars Bullinger
Lars Bullinger
MLMatthias Leisegang
Matthias Leisegang
LHLeo Hansmann
Leo Hansmann
We demonstrate an optimized oligonucleotide library-based approach for the identification of virus-reactive T-cell receptors using Epstein-Barr virus as an example. HEK293T served as antigen-presenting cells and were co-cultured with human T cells that were transduced with T-cell receptors in question. T-cell activation was detected by CD137 expression.

17 June 2026
Verified
Other
Open access
SSSerena Stadler
Serena Stadler
RBRafael B. Blasco
Rafael B. Blasco
VSVijay Kumar Singh
Vijay Kumar Singh
CDChristine Damm-Welk
Christine Damm-Welk
ABAmin Ben-Hamza
Amin Ben-Hamza
WWWilhelm Woessmann
Wilhelm Woessmann
Supplementary Data File S1 from Endogenous CD4+ T Cells That Recognize ALK and the NPM1::ALK Fusion Protein Can Be Expanded from Human Peripheral Blood